PRP for knee osteoarthritis is emerging as one of the most important joint-preserving treatment options for patients with knee pain, stiffness, and early to moderate arthritis. While traditional care has focused on exercise, pain relief, cortisone, and eventual knee replacement, growing Level 1 evidence suggests that platelet-rich plasma (PRP) injections can improve pain and function more effectively than older injectable options in appropriately selected patients. As understanding of knee osteoarthritis shifts from a simple “wear and tear” model to a biologically active disease process, PRP is increasingly being recognised as a meaningful treatment that may help reduce symptoms, improve mobility, and delay knee replacement in some patients.
Knee osteoarthritis is one of the most common causes of pain, stiffness, loss of mobility, and decline in quality of life in adults. For many years, the treatment pathway was largely built around symptom control: pain relief, exercise, anti-inflammatory medication, cortisone, and eventually knee replacement when the joint became bad enough.
That model is now being challenged.
We now have high-level evidence showing that platelet-rich plasma (PRP) injections for knee osteoarthritis can improve pain and function, often more effectively and for longer than hyaluronic acid, corticosteroid injection, or placebo in appropriately selected patients. Contemporary guidelines now recognise PRP as a meaningful treatment option for knee OA, particularly when the goal is to reduce symptoms, improve function, and potentially delay progression to arthroplasty [1].
This matters because knee osteoarthritis is not simply a “wear and tear” problem. It is a biologically active disease involving cartilage degeneration, synovial inflammation, subchondral bone change, and loss of joint homeostasis. That is precisely why regenerative and orthobiologic treatments have attracted so much interest [2].
What Is Knee Osteoarthritis (Knee OA)?
Knee osteoarthritis is a degenerative joint disease in which the cartilage lining the knee progressively breaks down, often accompanied by inflammation, osteophyte formation, joint space narrowing, subchondral bone change, pain, stiffness, swelling, and reduced function. It is a major cause of disability worldwide [2,3].
Importantly, symptoms and imaging do not always match perfectly. Some people have clear radiographic osteoarthritis with relatively modest symptoms, while others have disabling pain and functional loss even before radiographs look advanced. Good treatment decisions therefore require both imaging severity and clinical context.
How Knee Osteoarthritis Is Graded
The most widely used radiographic grading system is the Kellgren-Lawrence (KL) scale [4]. This classifies osteoarthritis from grade 0 to grade 4:
Grade 0: no radiographic evidence of osteoarthritis
Grade 1: doubtful OA, with possible tiny osteophytes and minimal change
Grade 2: mild OA, with definite osteophytes and possible joint space narrowing
Grade 3: moderate OA, with multiple osteophytes, definite joint space narrowing, sclerosis, and emerging deformity
Grade 4: severe OA, with marked joint space loss, large osteophytes, subchondral sclerosis, and definite bony deformity
In PRP research, many of the strongest clinical studies focus on early to moderate OA, especially KL grades 1 to 3. For example, Patel et al. studied early knee OA in KL grades 1 and 2, while Bansal et al. largely treated moderate disease, with most patients in KL grade 3 [5,6].
That is an important practical point: biologic treatments generally make the most sense before the joint has reached end-stage mechanical collapse.
Traditional Treatment for Knee Osteoarthritis
Historically, knee OA treatment has followed a fairly predictable sequence.
First comes conservative care: activity modification, weight management where relevant, muscle strengthening, physiotherapy, bracing, and oral analgesics or NSAIDs. If symptoms persist, patients are often offered injection-based symptom control such as corticosteroid or hyaluronic acid. When those measures no longer provide enough relief, the final step is usually partial or total knee replacement [2,3].
The limitation of this traditional pathway is that much of it is directed at symptom suppression rather than biological modification. Corticosteroid injections may reduce pain temporarily, but their benefit is often short-lived and they do not restore joint biology. Hyaluronic acid may help some patients. PRP emerged partly because clinicians were looking for an option that might do more than simply quiet pain for a few weeks [3,5].
Why PRP Is Changing Knee Osteoarthritis Treatment
PRP is an autologous biologic treatment prepared from the patient’s own blood. It concentrates platelets and their signaling molecules, which may help modulate inflammation, improve the joint environment, support chondrocyte activity, and promote a more favourable reparative response inside the osteoarthritic knee [2,3].
Over the last few years, the evidence base has strengthened considerably.
The ASPN evidence-based guideline concluded that PRP injection for knee OA is associated with superior long-term analgesia and physical functioning outcomes compared with hyaluronic acid, corticosteroid injection, and placebo at 6 and 12 months, assigning this a Level I, Grade B recommendation [1].
That is a meaningful shift. It places PRP above the older “temporary injectables” in the evidence hierarchy for many patients with knee OA.
Why PRP Dose Matters in Knee Osteoarthritis
One of the biggest problems in PRP literature has been the assumption that all PRP is interchangeable. It is not.
Different systems produce different platelet counts, different leukocyte content, different red cell contamination, and different injection volumes. That variability likely explains why some studies look far better than others. Multiple recent papers emphasise that platelet dose matters and that higher-dose preparations may be associated with better outcomes [6,7].
Berrigan et al. found that studies with positive outcomes at 6 and 12 months generally used substantially higher platelet doses than studies without positive differences.
Patel et al., in a Level 1 randomized trial, showed that an 8 mL “superdose” PRP injection containing about 5.65 billion platelets performed significantly better than a 4 mL injection containing about 2.82 billion platelets in early knee OA [5].
Bansal et al. went further, showing that a PRP formulation delivering about 10 billion platelets was associated with sustained improvement out to one year in moderate knee OA, along with better WOMAC, IKDC, and pain-free walking outcomes than hyaluronic acid. Their conclusion was explicit: an absolute count of 10 billion platelets appeared crucial for long-term chondroprotective effect in moderate knee OA [6].
So the conversation is no longer just “does PRP work?”
The better question is: what PRP, at what dose, with what formulation, for which patient, at what stage of disease?
Are Cellular Therapies Now Preferable?
If by “cellular therapies” we mean regenerative or orthobiologic treatments more broadly, then the answer is increasingly yes: the field has moved beyond a purely symptom-control model. Joint-preserving biologic strategies are now being considered earlier in the treatment pathway, particularly for patients seeking to preserve function, reduce pain, and delay arthroplasty. PRP sits clearly within that shift [2,3].
However, if by “cellular therapies” we mean mesenchymal stem cell (MSC)-type therapies specifically, the position is less certain. That is not necessarily because they are ineffective, but because the evidence base is not yet as mature, standardised, or clinically developed as it is for PRP. Study designs remain heterogeneous, preparation methods vary, regulatory frameworks differ, and outcomes are less consistent across the literature. As a result, MSC-based therapies remain promising, but they do not yet have the same depth of clinical evidence or guideline-level support as PRP for knee osteoarthritis.
The same ASPN guideline that supported PRP for knee OA also concluded that evidence for MSC injections is inconsistent and conflicting. Some studies show improved pain, function, walking distance, and quality of life, but others fail to show superiority over placebo or hyaluronic acid [1].
So the most evidence-based way to say this is:
PRP now has strong Level 1 support and should be considered a serious biologic treatment option for knee OA. Cell-based therapies are promising and increasingly discussed, but at present PRP has the more mature and consistent clinical evidence base.
That is an important distinction.
Can PRP Delay Knee Replacement?
Potentially, yes.
That does not mean PRP “cures” knee arthritis or makes surgery unnecessary forever. But it may reduce pain, improve function, and postpone the need for arthroplasty in selected patients. Real-world studies have specifically raised this possibility, with authors noting that PRP may help delay prosthetic surgery in patients with knee degenerative disease [2,3].
From a patient perspective, delay matters.
A knee replacement is a major operation. It can be an excellent procedure in the right patient at the right time, but it is not trivial. It involves hospital care, rehabilitation, risk of infection, thrombosis, stiffness, persistent pain, instability, and prosthesis-related problems such as wear or loosening [2].
Knee replacement is often highly effective, but it is not necessarily a once-in-a-lifetime solution: around 82% of total knee replacements last 25 years, and younger patients may face a lifetime revision risk above 20% [8].
Who Is a Good Candidate for PRP for Knee Osteoarthritis?
The best current role for PRP is not as a miracle cure and not as a replacement for every other treatment.
It is best understood as a joint-preserving biologic option for patients with symptomatic knee OA, particularly mild to moderate disease, who want a treatment with stronger evidence than traditional injectables and who are not yet at the stage where arthroplasty is clearly the right next step.
That may include:
- patients with KL grade 1 to 3 disease
- patients who have failed basic conservative care
- patients trying to avoid or delay cortisone cycles
- patients who are too young, too active, or not yet ready for knee replacement
- patients seeking a biologic approach rather than temporary symptom masking
The Real Takeaway
The traditional knee OA pathway was built around the idea that little could be done between basic conservative care and joint replacement.
That is no longer true.
PRP has now moved into a different category of evidence. It is not just an experimental add-on. There is now Level 1 evidence and guideline-level support showing that PRP can outperform hyaluronic acid, corticosteroid injections, and placebo for pain and function at medium-term follow-up in knee osteoarthritis [1].
At the same time, the literature makes something else very clear: PRP quality matters. Dose matters. Formulation matters. Leukocyte content matters. Not all PRP is the same, and outcomes should not be judged as though it were a single uniform product [6,7].
For the right patient, PRP now deserves to be considered before knee replacement, not after everything else has failed.
And in a condition where replacements may eventually lead to further surgery, that shift is clinically significant.
Related Articles
- What Is PRP Therapy and How Does It Work?
- Why PRP May not have Worked
- Treating Spinal Pain: A Precision Framework for PRP and Biologic Spine Treatments
- Not All PRP Is the Same: Why Platelet Dose (High-Dose PRP) Matters
- How to Choose a High-Quality MRI Provider
- Does Medicare Cover PRP?
- Hyaluronic Acid Injections – What you should Know
- What Are Stem Cells?
- PRP vs Steroids: Which is Better?
Frequently Asked Questions About PRP for Knee Osteoarthritis
Below are some commonly asked questions. For a full list, visit our frequently asked questions page.
Is PRP effective for knee osteoarthritis?
Yes, PRP has growing high-level evidence for knee osteoarthritis, particularly in patients with mild to moderate disease. Studies and recent evidence-based guidance suggest PRP can improve pain and function more effectively than hyaluronic acid, corticosteroid injection, or placebo at 6 and 12 months in appropriately selected patients. The important caveat is that not all PRP is the same, and outcomes may depend on dose, formulation, and technique.
Who is a good candidate for PRP for knee osteoarthritis?
PRP is generally most relevant for patients with symptomatic mild to moderate knee osteoarthritis, especially those with Kellgren-Lawrence grade 1 to 3 disease. It may be particularly useful for patients who have not improved enough with exercise, weight optimisation, physiotherapy, or simple pain relief, and who want a joint-preserving option before considering knee replacement.
Can PRP delay knee replacement?
Potentially, yes. PRP does not cure knee osteoarthritis, but it may reduce pain, improve function, and help some patients delay progression to knee replacement. That can be important, especially in younger or more active patients, because knee replacement is major surgery and is not always a once-in-a-lifetime solution.
Is all PRP the same for knee osteoarthritis?
No. This is one of the most important points patients should understand. PRP preparations vary in platelet dose, leukocyte content, red cell contamination, volume, and overall formulation. Increasing evidence suggests that higher-quality, dose-conscious PRP may produce better outcomes than lower-dose or poorly characterised preparations.
Is PRP better than cortisone for knee arthritis?
For many patients, PRP appears to offer more durable benefit than corticosteroid injection. Cortisone may reduce symptoms temporarily, but PRP has shown better medium-term pain and function outcomes in many studies of knee osteoarthritis. PRP is best thought of as a biologic joint-preserving treatment, whereas cortisone is primarily a short-term symptom-control injection.
References
1. D’Souza RS, Her YF, Hussain N, Karri J, Schatman ME, Calodney AK, et al. Evidence-based clinical practice guidelines on regenerative medicine treatment for chronic pain: a consensus report from a multispecialty working group. J Pain Res. 2024;17:2951-3001. doi:10.2147/JPR.S480559.
2. Catalán JM, Escarrer-Garau G, Estrany-Celià MDM, Parra C, Arbona-González L, Mercader-Barceló J, Dos-Anjos S. Intraosseous and Intra-Articular Platelet-Rich Plasma for Severe Knee Osteoarthritis: A Real-World-Outcomes Initiative. J Clin Med. 2025 May 22;14(11):3627. doi: 10.3390/jcm14113627. PMID: 40507389; PMCID: PMC12155101.
3. Prost D, Bardot T, Baud A, Calvo A, Aumont S, Collado H, et al. Long term improvement of knee osteoarthritis after injection of single high/very high volume of very pure PRP: a retrospective analysis of patients optimally managed in dedicated centers. Regen Ther. 2024;25:203-212. doi:10.1016/j.reth.2023.12.006.
4. Kohn MD, Sassoon AA, Fernando ND. Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis. Clin Orthop Relat Res. 2016 Aug;474(8):1886-93. doi: 10.1007/s11999-016-4732-4. Epub 2016 Feb 12. PMID: 26872913; PMCID: PMC4925407.
5. Patel S, Gahlaut S, Thami T, Chouhan DK, Jain A, Dhillon MS. Comparison of conventional dose versus superdose platelet-rich plasma for knee osteoarthritis: a prospective, triple-blind, randomized clinical trial. Orthop J Sports Med. 2024;12(2):23259671241227863. doi:10.1177/23259671241227863.
6. Bansal H, Leon J, Pont JL, Wilson DA, Bansal A, Agarwal D, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: correct dose critical for long term clinical efficacy. Sci Rep. 2021;11(1):3971. doi:10.1038/s41598-021-83025-2.
7. Berrigan WA, Bailowitz Z, Park A, Reddy A, Liu R, Lansdown D. A greater platelet dose may yield better clinical outcomes for platelet-rich plasma in the treatment of knee osteoarthritis: a systematic review. Arthroscopy. 2025;41(3):809-817. doi:10.1016/j.arthro.2024.03.018.
8. Evans JT, Walker RW, Evans JP, Blom AW, Sayers A, Whitehouse MR. How long does a knee replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up. Lancet. 2019;393(10172):655-663. doi:10.1016/S0140-6736(18)32531-5.
Author: Dr Kirralee Sherif (PhD)
